Skip to main content

Table 1 Characteristic of studies included in the meta-analysis

From: Effect of diabetes mellitus on survival in patients with gallbladder Cancer: a systematic review and meta-analysis

First author, publication year

Country

Sample size

Male/female

Mean age (year)

Average follow-up duration (year)

Effect measure

Diabetes assessment

Adjusted factors

Coughlin, 2004 [26]

USA

1,056,243

467,922/588321

56.7

12.5

RR

Self-report

Age, smoking, race, BMI, exercise, education

Yagyu, 2004 [27]

Japan

113,394

47,673/65721

40–89

9.7

HR

Self-report

Age, gender, history of hepatic disease

Swerdlow, 2005 [28]

UK

28,900

15,688/13212

NA

18.0

SMR

Medical record

Age, region, duration

Tseng, 2009 [34]

Taiwan

244,920

113,347/131573

NA

12

SMR

Medical record

Age, gender

Lam, 2011 [29]

Asia, Australia

367,361

216,743/150618

48

4

HR

Self-report or WHO diagnostic criteria

Age

Seshasai, 2011 [30]

Members of ERFC

820,900

426,868/394032

55

NA

HR

Medical record

Age, gender, smoking, BMI

Campbell, 2012 [35]

USA

1,053,831

467,143/586688

63.1

12.1

RR

Self-report

Age, BMI, education, exercise, NSAIDs, alchhol

Currie, 2012 [31]

UK

112,408

54,086/58322

67.8

2

HR

Read code classification

Age, gender, smoking, Charlson comorbidity index, year of diagnosis

Harding, 2015 [32]

Australia

953,382

506,312/447070

T1DM: 27.4

T2DM: 60.4

10

SMR

Medical record

Age

Chen, 2017 [33]

Asia

771,297

391,619/379678

53.9

12.7

HR

Self-report

Age, gender, BMI, smoking, alcohol, education, region

  1. ERFC Emerging Risk Factors Collaboration, T1DM Type 1 Diabetes Mellitus, T2DM Type 2 Diabetes Mellitus, RR Relative Risk, HR Hazard Ratio, SMR Standard Mortality Ratio, WHO World Health Organization, BMI Body Mass Index, NSAIDs Nonsteroidal Anti-inflammatory Drugs